Slow the taper significantly or pause entirely until symptoms resolve
For a patient on only 5 mg amitriptyline for 2 weeks experiencing tinnitus and anxiety, you should slow or temporarily halt the taper, as these symptoms likely represent withdrawal phenomena despite the very low dose and short duration of use.
Understanding the Clinical Picture
The patient's symptoms of tinnitus (ringing in ears) and anxiety during tapering are consistent with tricyclic antidepressant withdrawal syndrome 1. The FDA label explicitly lists tinnitus and anxiety as adverse effects of amitriptyline, and withdrawal symptoms can include "irritability, restlessness, and dream and sleep disturbance" 1. Even after short-term use at low doses, some patients experience withdrawal phenomena 2.
Immediate Management Strategy
1. Pause or Slow the Taper
- Hold at current dose (or return to the last tolerated dose if already discontinued) until symptoms stabilize for at least 1-2 weeks
- The general principle from medication discontinuation guidelines is to "taper medication slowly to avoid withdrawal symptoms" 3
2. Differentiate Withdrawal from Other Causes
For the tinnitus:
- Tinnitus is listed as a known CNS adverse effect of amitriptyline 1
- However, primary tinnitus evaluation requires ruling out underlying pathology 4
- If tinnitus is new-onset and coincides with tapering, withdrawal is most likely
- If tinnitus persists beyond 2-4 weeks after stabilization, consider otologic evaluation
For the anxiety:
- Anxiety is a recognized withdrawal symptom from tricyclic antidepressants 1
- The FDA label warns about "emergence of anxiety, agitation, panic attacks, insomnia, irritability" especially during dose adjustments 1
- Monitor closely for worsening or suicidal ideation, which requires immediate intervention
Revised Tapering Approach
Given the patient is experiencing symptoms at 5 mg after only 2 weeks:
Option 1: Very Gradual Taper (Recommended)
- Once symptoms resolve, reduce by 1-2 mg every 2-4 weeks
- Example: 5 mg → 3-4 mg (hold 2-4 weeks) → 2 mg (hold 2-4 weeks) → 1 mg (hold 2-4 weeks) → stop
- This may require liquid formulation or compounded doses 5, 6
Option 2: Pause and Reassess
- Hold at 5 mg for 4-6 weeks to allow symptom resolution
- If symptoms persist, this suggests they may not be withdrawal-related
- If symptoms resolve, attempt slower taper as above
Monitoring Plan
Weekly check-ins for the first 2-4 weeks to assess:
- Severity of tinnitus (scale 1-10)
- Anxiety symptoms (using standardized scale if possible)
- Sleep quality
- Any new neurological symptoms
- Suicidal ideation (critical given FDA black box warning) 1
Then every 2-4 weeks during continued tapering 6.
Common Pitfalls to Avoid
Don't assume low dose = no withdrawal risk: Even 5 mg can cause withdrawal symptoms in susceptible individuals 2, 7
Don't continue rapid tapering: The insomnia guideline specifically warns that "rebound insomnia and withdrawal can be minimized by gradually tapering both the dose and frequency" 8
Don't miss psychiatric emergencies: Patients with tinnitus and severe anxiety require "prompt identification and intervention, as suicide has been reported" 4
Don't ignore persistent tinnitus: If tinnitus continues beyond withdrawal period, it requires proper otologic evaluation as it affects quality of life significantly 9
Symptomatic Management During Taper
While tapering:
- For anxiety: Consider short-term use of non-pharmacologic interventions (relaxation techniques, cognitive behavioral approaches)
- For tinnitus: Sound therapy or white noise may provide temporary relief 4
- Avoid adding new medications that could complicate the clinical picture unless absolutely necessary
The key principle: withdrawal symptoms from tricyclic antidepressants can occur even at very low doses and short durations 2, 7. The patient's symptoms warrant a much slower, more cautious approach than initially planned.